HIV drug stabilizes disease progression in metastatic colorectal cancer
Many cancers exhibit high levels of the reverse transcriptase enzyme. Single-agent lamivudine, a reverse transcriptase inhibitor, stopped disease progression in over 25% of patients with fourth-line refractory metastatic colorectal cancer. These results provide evidence for the evaluation of reverse transcriptase inhibitors as a new class of anti-cancer drugs.
Materials provided by Massachusetts General Hospital. Note: Content may be edited for style and length.
Source link aaaaa